Cutaneous T-Cell Lymphoma: Overview and Nursing Perspectives
Section snippets
Epidemiology
MF and SzS are the most common of the CTCLs with MF being the most prevalent. It is difficult to determine the actual prevalence of the disorder, since it is often indolent and chronic, lasting in many cases for decades. CTCL is most common in the later decades of life, beginning on average at the 5th or 6th decade, but any age group can be affected. The most recent U.S. study on incidence revealed a 2.9 × 10−6 increase per decade since 1973 with a current estimated incidence of 6.4 per million
Etiology
The cause of CTCL remains unknown despite epidemiologic attempts to establish an infectious, environmental, or genetic link [5]. Some cases of multiple family members developing CTCL have been reported; however, there are no established genetic links [6]. Its pathology reflects a cancer of the immune system whereby the skin-homing T cells, preprogrammed to protect the skin, expand clonally, function in an activated state, and achieve clonal dominance [2]. This neoplastic, clonal expansion,
Prognosis
Prognosis is good for patients who present with early-stage CTCL, with longevity approaching that of age-matched control groups and with relatively few reported disease-related deaths. In the advanced stages (IIB–IVB), however, the prognosis is less favorable. Disease-related deaths usually involve the overt failure of the immune system, leading to sepsis or other opportunistic infections [7].
Skin manifestations and symptoms
In the less common variants of MF, unique lesions are observed. Granulomatous slack skin presents as infiltrating lesions, primarily of the axillary/inguinal folds. Over time, the skin in these areas becomes atrophic and loses elasticity, and excessive skin folds are noted. Folliculotropic MF infiltrates hair follicles and produces localized alopecia. Pagetoid reticulosis is characterized by a localized keratotic or psoriasiform plaque that develops slowly and usually is found on a lower
Diagnosis
The diagnosis of CTCL may be delayed by the difficulty in obtaining a diagnostic skin biopsy. It also is delayed when patients ignore asymptomatic, slow-growing, or changing lesions for months to years. It is common for patients to report the existence of the disease for some time before medical attention is sought or before a primary care physician refers the patient to a specialist. Often, multiple biopsies done over time (months to years) are required so that a histopathologic diagnosis can
Treatment
A multidisciplinary approach often is required for patients who have more extensive skin involvement, generally greater than stage IA. For these patients, an interdisciplinary plan of care involving the dermatologist, oncologist, and radiation oncologist often improves outcomes and establishes a network of providers for multiple therapeutic pathways [16].
There are many therapeutic options for CTCL. This variety of options generally means there is no one or two therapies that work for most
Nursing role
Nursing care is a critical element to the successful care of patients who have CTCL and involves administering hands-on care, acting as the patient's advocate, and educating the patient and family members on a multitude of topics. The nurse is instrumental as a liaison with the physician, other health care providers (oncologist, radiation oncologist, dietician, and pharmacist), social services, community agencies, and family members. The author has found that patients are comfortable
Support and patient resources
The CLF was established in 1998 and formerly was known as the “Mycosis Fungoides Foundation.” The CLF is dedicated to supporting people diagnosed as having a cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. Among its many programs, the CLF partners with industry sponsors and medical centers to promote educational forums around the country through Web casts and day-long symposiums. It also provides two on-line support groups, one geared
Summary
CTCL is an uncommon and complex malignancy of the immune system with a wide range of clinical presentations primarily involving the skin. Involvement of lymph nodes and distant organs is also possible. The disease is chronic by nature and as such affords the dermatologist and dermatology nurse an opportunity to provide care for the patient on a long-term basis. An extensive menu of skin-directed and/or systemic treatment options exists. Best practices in management involve multidisciplinary
References (39)
- et al.
Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system
J Am Acad Dermatol
(2005) - et al.
Update on erythrodermic cutaneous T-cell lymphoma: report to the International Society for Cutaneous Lymphomas
J Am Acad Dermatol
(2002) - et al.
Long-term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma
J Am Acad Dermatol
(1989) - et al.
Long term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
J Am Acad Dermatol
(1996) - et al.
Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V-beta gene expansion
Blood
(1997) The new World Health Organization-European Organization for research and treatment of cancer classification for cutaneous lymphomas: a practical marriage of two giants
Br J Dermatol
(2005)- et al.
The pathogenesis of mycosis fungoides
N Engl J Med
(2004) - et al.
Immunopathogenesis and therapy of cutaneous T cell lymphoma
J Clin Invest
(2005) - et al.
Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002
Arch Dermatol
(2007) - et al.
Mycosis fungoides: review of epidemiological observations
Dermatology
(2000)
Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients
J Am Acad Dermatol
Significant impact of cutaneous T-cell lymphoma on patient's quality of life: results of a 2005 national cutaneous lymphoma foundation survey
Cancer
Other systemic lymphomas with skin infiltration
Treatment of cutaneous T-cell lymphoma/mycosis fungoides
Dermatol Nurs
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression
Arch Dermatol
Mycosis fungoides and the Sezary syndrome
Semin Oncol
Treatment of cutaneous T-cell lymphoma: current status and future directions
Am J Clin Dermatol
Mycosis fungoides and Sezary syndrome: an update
Curr Oncol Rep
Treatment planning in cutaneous T-cell lymphoma
Dermatol Ther
Cited by (6)
Top Ten Tips Palliative Care Clinicians Should Know about Caring for Patients with Cutaneous T Cell Lymphoma
2022, Journal of Palliative MedicineNursing best practice referral algorithm for the early detection of mycosis fungoides
2016, Journal of the Dermatology Nurses' AssociationTherapeutic/treatment modalities
2016, Dermatologic Nursing Essentials: A Core Curriculum: Third EditionHistone deacetylase inhibitors in cutaneous T-cell lymphoma: Nursing considerations
2013, Journal of the Dermatology Nurses' AssociationHistone deacetylase inhibitors: Novel agents in cancer treatment
2013, Clinical Journal of Oncology NursingLoss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma
2011, Journal of Clinical Investigation